Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Millendo Raises $62m, Licenses AstraZeneca Drug

This article was originally published in Scrip

Executive Summary

Millendo Therapeutics raised $62m in a Series B round led by New Enterprise Associates and the endocrine disorder-focused biotech firm licensed a polycystic ovary syndrome (PCOS) drug candidate from AstraZeneca PLC in a deal that will widen the company's focus.

You may also be interested in...



Deal Watch, Focus On Acquisitions: Emergent Acquires PaxVax, Pair Of Commercialized Vaccines

Emergent gets vaccines for cholera and typhoid fever in PaxVax buyout. By taking over the OvaScience shell to go public, Millendo expects to take lead candidate livelotide into a pivotal study early next year.

GSK Spin-Out NeRRe Raises £23m For NK Antagonists

New cash will fund further clinical testing of NeRRe's two neurokinin receptor antagonists for cough and hot flashes.

Finance Watch: Biopharma IPOs Slow But SPACs Back On The Go

Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.

Topics

UsernamePublicRestriction

Register

SC064141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel